Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4302407 | 0.91 | TP53 (0.49) | MEN1KMT2AGPR119TP53OPRK1 | |
| SCHEMBL4307829 | 0.90 | MEN1 (0.48) | MEN1KMT2AGPR119TP53OPRK1 | |
| SCHEMBL4318763 | 0.90 | MEN1 (0.53) | MEN1KMT2AGPR119STSPGR | |
| SCHEMBL4312794 | 0.90 | MEN1 (0.62) | MEN1KMT2AGPR119 | |
| SCHEMBL4306298 | 0.89 | MEN1 (0.57) | MEN1KMT2AGPR119TP53STS | |
| SCHEMBL4314810 | 0.89 | MEN1 (0.57) | MEN1KMT2AGPR119TP53STS | |
| SCHEMBL4311539 | 0.88 | MEN1 (0.56) | MEN1KMT2AGPR119TP53STS | |
| SCHEMBL4306686 | 0.88 | MEN1 (0.56) | MEN1KMT2AGPR119TP53 | |
| SCHEMBL4311345 | 0.86 | KMT2A (0.58) | MEN1KMT2AGPR119TP53 | |
| SCHEMBL4307751 | 0.86 | KMT2A (0.58) | MEN1KMT2AGPR119TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488741-B2 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | UCB PHARMA, S.A. (BE) | 2009-02-10 | — | — | US | claimed |
| EP-1556045-B1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB SA (BE) | 2006-08-02 | — | — | EP | claimed |
| US-20060128753-A1 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | UCB, S.A. (BE) | 2006-06-15 | — | — | US | claimed |
| EP-1556045-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2005-07-27 | — | — | EP | claimed |
| WO-2004030668-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2004-04-15 | — | — | WO | claimed |
| US-7488741-B2 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | UCB PHARMA, S.A. (BE) | 2009-02-10 | — | — | US | disclosed |
| EP-1693061-A1 | Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases | UCB, S.A. (BE) | 2006-08-23 | — | — | EP | disclosed |
| EP-1556045-B1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB SA (BE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060128753-A1 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | UCB, S.A. (BE) | 2006-06-15 | — | — | US | disclosed |
| EP-1556045-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004030668-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128753-A1 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | PNMT, HTR5A, HTR4 | MEN1 4456/4885KMT2A 1360/4885GPR119 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.